WHEN TO CONSIDER XCOPRI
Are your patients still experiencing seizures? It may be time to consider XCOPRI
XCOPRI® (CENOBAMATE TABLETS) CV IS INDICATED FOR THE TREATMENT
OF PARTIAL-ONSET SEIZURES IN ADULT PATIENTS1
XCOPRI received FDA-approval in 20201
0 prescriptions have been written to date for XCOPRI2*
Flexible, once-daily dosing to take patients through their treatment journey1
with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(1):28-48.
MOA
XCOPRI is thought to work via a multimodal mechanism of action1*
XCOPRI has been shown to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents, including inhibiting the component of the sodium current1

XCOPRI is also a positive allosteric modulator of the y-aminobutyric acid (GABAA) ion channel1
